The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Open accessAbstract
BACKGROUND: Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer. METHODS: We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 1.0 cm to receive 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period followed by either 75 mg of intravenous cisplatin per square meter on day 2 (intravenous-therapy group) or 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 (intraperitoneal-therapy group). Treatment was given every three weeks for six cycles. Quality of life was assessed. RESULTS: Of 429 patients who underwent randomization, 415 were eligible. Grade 3 and 4 pain, fatigue, and hematologic, gastrointestinal, metabolic, and neurologic toxic effects were more common in the intraperitoneal-therapy group than in the intravenous-therapy group (P< or =0.001). Only 42 percent of the patients in the intraperitoneal-therapy group completed six cycles of the assigned therapy, but the median duration of progression-free survival in the intravenous-therapy and intraperitoneal-therapy groups was 18.3 and 23.8 months, respectively (P=0.05 by the log-rank test). The median duration of overall survival in the intravenous-therapy and intraperitoneal-therapy groups was 49.7 and 65.6 months, respectively (P=0.03 by the log-rank test). Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment. CONCLUSIONS: As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Self-citationCannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
A Common Allele on Chromosome 9 Associated with Coronary Heart Disease
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., Hinds, D. A., Pennacchio, L. A., Tybjaerg-Hansen, A., Folsom, A. R., et al. (2007) · Science · doi:10.1126/science.1142447 · Cited by 1,587
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 845
Self-citationZhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Self-citationNCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.-M., Cristea, M., DeRosa, M., Eisenhauer, E. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0007 · Cited by 715
Self-citationHigh-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Hensley, M., & Barakat, R. R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.051 · Cited by 634
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Castells, M. C., Tennant, N. M., Sloane, D. E., Ida Hsu, F., Barrett, N. A., Hong, D. I., Laidlaw, T. M., Legere, H. J., Nallamshetty, S. N., Palis, R. I., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.044 · Cited by 600
Chi, D. S., Eisenhauer, E. L., Zivanovic, O., Sonoda, Y., Abu-Rustum, N. R., Levine, D. A., Guile, M. W., Bristow, R. E., Aghajanian, C., & Barakat, R. R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.018 · Cited by 591
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S. P., & Kaye, S. B. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3432 · Cited by 562
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Chua, T. C., Yan, T. D., Saxena, A., & Morris, D. L. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a45d86 · Cited by 532
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Salani, R., Backes, F. J., Fung Kee Fung, M., Holschneider, C. H., Parker, L. P., Bristow, R. E., & Goff, B. A. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.008 · Cited by 428
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
Stuart, G. C. E., Kitchener, H., Bacon, M., duBois, A., Friedlander, M., Ledermann, J., Marth, C., Thigpen, T., & Trimble, E. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821b2568 · Cited by 425
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Self-citationColombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Optimal primary surgical treatment for advanced epithelial ovarian cancer
Elattar, A., Bryant, A., Winter-Roach, B. A., Hatem, M., & Naik, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007565.pub2 · Cited by 403
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Clinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Kampan, N. C., Madondo, M. T., McNally, O. M., Quinn, M., & Plebanski, M. (2015) · BioMed Research International · doi:10.1155/2015/413076 · Cited by 362
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.022 · Cited by 362
Self-citationIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Ishigami, H., Fujiwara, Y., Fukushima, R., Nashimoto, A., Yabusaki, H., Imano, M., Imamoto, H., Kodera, Y., Uenosono, Y., Amagai, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8613 · Cited by 353
Yan, T. D., Black, D., Sugarbaker, P. H., Zhu, J., Yonemura, Y., Petrou, G., & Morris, D. L. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9487-4 · Cited by 343
Yan, T. D., Black, D., Savady, R., & Sugarbaker, P. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1142 · Cited by 343
Lessons from BRCA: the Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.702 · Cited by 342
Ten-Year Relative Survival for Epithelial Ovarian Cancer
Baldwin, L. A., Huang, B., Miller, R. W., Tucker, T., Goodrich, S. T., Podzielinski, I., DeSimone, C. P., Ueland, F. R., van Nagell, J. R., & Seamon, L. G. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318264f794 · Cited by 336
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Alyami, M., Hübner, M., Grass, F., Bakrin, N., Villeneuve, L., Laplace, N., Passot, G., Glehen, O., & Kepenekian, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30318-3 · Cited by 331
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206400109 · Cited by 328
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Immunological Functions of the Omentum
Meza-Perez, S., & Randall, T. D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.03.002 · Cited by 326
Coccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 325
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004173 · Cited by 322
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 319
Galanis, E., Hartmann, L. C., Cliby, W. A., Long, H. J., Peethambaram, P. P., Barrette, B. A., Kaur, J. S., Haluska, P. J., Aderca, I., Zollman, P. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2762 · Cited by 317
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Berek, J. S., Chen, L.-M., Cristea, M., DeRosa, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0039 · Cited by 309
Self-citationPrimary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Yan, T. D., Welch, L., Black, D., & Sugarbaker, P. H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl428 · Cited by 308
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Helm, C. W., Richard, S. D., Pan, J., Bartlett, D., Goodman, M. D., Hoefer, R., Lentz, S. S., Levine, E. A., Loggie, B. W., Metzinger, D. S., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c50cde · Cited by 302
Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Self-citationKorean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281
Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.030 · Cited by 280
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
Harris, J. C., Scully, M. A., & Day, E. S. (2019) · Cancers · doi:10.3390/cancers11121836 · Cited by 278
Bakrin, N., Bereder, J. M., Decullier, E., Classe, J. M., Msika, S., Lorimier, G., Abboud, K., Meeus, P., Ferron, G., Quenet, F., et al. (2013) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2013.09.030 · Cited by 272
Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles
Rodzinski, A., Guduru, R., Liang, P., Hadjikhani, A., Stewart, T., Stimphil, E., Runowicz, C., Cote, R., Altman, N., Datar, R., et al. (2016) · Scientific Reports · doi:10.1038/srep20867 · Cited by 271
Odunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 270
Self-citationIntraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.12.013 · Cited by 270
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
Xiao, H., Song, H., Yang, Q., Cai, H., Qi, R., Yan, L., Liu, S., Zheng, Y., Huang, Y., Liu, T., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.049 · Cited by 200
Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., & Ioannidis, J. P. A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj443 · Cited by 187
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Arend, R. C., Londoño-Joshi, A. I., Samant, R. S., Li, Y., Conner, M., Hidalgo, B., Alvarez, R. D., Landen, C. N., Straughn, J. M., & Buchsbaum, D. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.005 · Cited by 161
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153
Self-citationShen, W., Chen, X., Luan, J., Wang, D., Yu, L., & Ding, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11998 · Cited by 138
Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer
Carter, N. J., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767150-00009 · Cited by 107
Targeted delivery of platinum-taxane combination therapy in ovarian cancer
Desale, S. S., Soni, K. S., Romanova, S., Cohen, S. M., & Bronich, T. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.007 · Cited by 61
Determinants of quality of life in ovarian cancer survivors: a pilot study
Teng, F. F., Kalloger, S. E., Brotto, L., & McAlpine, J. N. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30513-2 · Cited by 42
State of the science: Contemporary front-line treatment of advanced ovarian cancer
Hinchcliff, E., Westin, S. N., & Herzog, T. J. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.04.021 · Cited by 26
Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
Jewell, A., McMahon, M., & Khabele, D. (2018) · Cancers · doi:10.3390/cancers10090296 · Cited by 24
Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0669-0 · Cited by 17
Current First-line Therapy for Ovarian Cancer: A Comprehensive Review
Pierce, S. R., & Clark, L. H. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000613 · Cited by 17
Skaznik-Wikiel, M. E., Lesnock, J. L., McBee, W. C., Beriwal, S., Zorn, K. K., Richard, S. D., Krivak, T. C., & Edwards, R. P. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e318234f833 · Cited by 15
Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04235-z · Cited by 12
Metadata
- Authors
- Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-05
- Volume
- 354
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2154175915
- Cited by
- 2,625
- References
- 18
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.